Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (61-70 of 468) with videos related to

Pageof 47
Sort By:
JAMA Oncology|February 17, 2022
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility CriteriaJennifer J Gao, Richard Pazdur, Julia A Beaver
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Rare cancer trial design: lessons from FDA approvalsHimabindu Gaddipati, Ke Liu, Anne Pariser, et al.
Cancer Journal (Sudbury, Mass.)|May 26, 2018
The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory EnvironmentKirsten B Goldberg, Gideon M Blumenthal, Richard Pazdur
Blood|August 5, 2017
Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugsAnn T Farrell, Kirsten B Goldberg, Richard Pazdur
The New England Journal of Medicine|April 14, 2016
Seamless Oncology-Drug DevelopmentTatiana M Prowell, Marc R Theoret, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
JAMA Oncology|January 20, 2022
Accelerated Approval Is Not Conditional Approval: Insights From International Expedited Approval ProgramsGautam U Mehta, R Angelo de Claro, Richard Pazdur
Pediatric Blood & Cancer|January 22, 2013
The impact of the written request process on drug development in childhood cancerKristen M Snyder, Gregory Reaman, Debbie Avant, et al.
Nature Reviews. Clinical Oncology|February 21, 2024
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefitKelly J Norsworthy, Rosa J Lee-Alonzo, Richard Pazdur
Pageof 47

Showing results (61-70 of 468) with videos related to

Sort By:
Pageof 47
JAMA Oncology|February 17, 2022
Reexamination of Patient Autonomy and Prior Therapies in Oncology Clinical Trial Eligibility CriteriaJennifer J Gao, Richard Pazdur, Julia A Beaver
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2012
Rare cancer trial design: lessons from FDA approvalsHimabindu Gaddipati, Ke Liu, Anne Pariser, et al.
Cancer Journal (Sudbury, Mass.)|May 26, 2018
The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory EnvironmentKirsten B Goldberg, Gideon M Blumenthal, Richard Pazdur
Blood|August 5, 2017
Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugsAnn T Farrell, Kirsten B Goldberg, Richard Pazdur
The New England Journal of Medicine|April 14, 2016
Seamless Oncology-Drug DevelopmentTatiana M Prowell, Marc R Theoret, Richard Pazdur
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approvalMartin H Cohen, John R Johnson, Richard Pazdur
The Oncologist|April 5, 2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
JAMA Oncology|January 20, 2022
Accelerated Approval Is Not Conditional Approval: Insights From International Expedited Approval ProgramsGautam U Mehta, R Angelo de Claro, Richard Pazdur
Pediatric Blood & Cancer|January 22, 2013
The impact of the written request process on drug development in childhood cancerKristen M Snyder, Gregory Reaman, Debbie Avant, et al.
Nature Reviews. Clinical Oncology|February 21, 2024
FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefitKelly J Norsworthy, Rosa J Lee-Alonzo, Richard Pazdur
Pageof 47